Datum Källa Rubrik Typ Alternativ
2022-12-06 Redeye Redeye: Redeye Initiates Coverage of Enzymatica Analyser Ladda ner | Visa Stäng
2022-11-16 Enzymatica Enzymatica AB: Enzymatica och University of Kent startar studie för att undersöka hur elitidrottare kan förebygga virusinfektioner i de övre luftvägarna Pressreleaser Ladda ner | Visa Stäng
2022-11-16 Enzymatica Enzymatica AB: Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes Pressreleaser Ladda ner | Visa Stäng
2022-11-03 Penser Access Penser Access: Inte helt ute ur coronatunneln - Enzymatica Analyser Visa Stäng
2022-11-02 Enzymatica Enzymatica AB: Kvartalsrapport Q3/2022: En bredare roll för ColdZyme adderar potential för framtiden Rapporter Ladda ner | Visa Stäng
2022-11-02 Enzymatica Enzymatica AB: Interim report Q3/2022: A broader role for ColdZyme adds potential for the future Rapporter Ladda ner | Visa Stäng
Rapporter | 2 Nov 2022 | Enzymatica

Enzymatica AB: Interim report Q3/2022: A broader role for ColdZyme adds potential for the future

  

Significant Significant events after the quarter
events during
the quarter

  • To ensure · On October 31, the journal Respiratory Research published a

the long-term study from the Medical University of Innsbruck, Austria, which
financing of shows that ColdZyme blocks the widespread and highly
the business, transmissible omicron variants BA.4 and BA.5 from adhering to
in September and infecting human cells. According to the research group that
the company conducted the study, this opens the possibility that ColdZyme
raised about can be applied in the prevention of SARS-CoV-2 spreading.
SEK 74.7 Continued clinical trials are needed to establish the effect in
million vivo.
before issue
expenses
through a
rights issue.
The rights
issue was
fully
subscribed,
including 63
percent
subscribed
with the
support of
subscription
rights and 1
percent
without the
support of
subscription
rights. The
company’s
three largest
shareholders,
along with
the CEO and
the Chairman
of the Board,
subscribed
for the
remainder, 36
percent, in
accordance
with the
guarantee
commitments.

Other events
during the
quarter

  • The

company’s mouth
spray was
launched in
Mexico and
Turkey,
expanding the
company’s
market by more
than 200
million
consumers.

Third quarter January-September

  • Net sales · Net sales reached SEK 32.3

reached SEK (38.5) million.
18.5 (15.4) · The operating result totaled SEK
million. -46.6 (-34.7) million.

  • The · Earnings per share, basic and

operating diluted, were SEK -0.31 (-0.24).
result · Cash flow from operating
totaled SEK activities totaled SEK 37.7 (-29.3)
-12.6 (-6.0) million.
million. · Net cash totaled SEK 57.3 (35.7)

  • The million.

operating
result
includes non
-recurring
costs of SEK
6.2 million
as an effect
of
renegotiation
of agreements
with two of
the company’s
business
partners.

  • Earnings

per share,
basic and
diluted, were
SEK -0.08 (
-0.04).

  • Cash flow

from
operating
activities
totaled SEK
-6.0 (-16.2)
million.

  • Cash flow

from
financing
activities
totaled SEK
81.1 million,
of which SEK
69.1 refer to
rights issue
carried out
in September.

”The study that has been published in Respiratory Research shows ColdZyme has the potential to move from a cold remedy product to a complement to vaccines in the protection against Covid-19. After a couple of very hard years, many signs now indicate that Enzymatica has passed the austerity caused by the pandemic. We see good possibilities of expanding in new and existing markets, we have a good organization in place, and strong business partners. I am convinced that there are a number of exciting and successful years ahead of us”, said Claus Egstrand, CEO of Enzymatica.

The full year-end report is available on: www.enzymatica.com/investors/financial-reports

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET
on 2 November 2022.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica’s Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: certifiedadviser@penser.se

2022-11-01 Enzymatica Enzymatica AB: New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells Pressreleaser Ladda ner | Visa Stäng
2022-11-01 Enzymatica Enzymatica AB: Ny studie bekräftar: ColdZyme hindrar virus som orsakar Covid-19 från att fästa vid mänskliga luftvägsceller Pressreleaser Ladda ner | Visa Stäng
2022-08-26 Enzymatica Enzymatica AB: Enzymatica announces outcome of new rights issue Pressreleaser Ladda ner | Visa Stäng
2022-08-26 Enzymatica Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2022-08-18 Enzymatica Enzymatica AB: Enzymatica offentliggör tilläggsprospekt Pressreleaser Ladda ner | Visa Stäng
2022-08-18 Enzymatica Enzymatica AB: Enzymatica publishes supplementary prospectus Pressreleaser Ladda ner | Visa Stäng
2022-08-16 Enzymatica Enzymatica AB: ColdZyme also blocks omicron variants BA.4 and BA.5 Pressreleaser Ladda ner | Visa Stäng
2022-08-16 Enzymatica Enzymatica AB: ColdZyme blockerar även omikronvarianterna BA.4 och BA.5 Pressreleaser Ladda ner | Visa Stäng
2022-08-05 Enzymatica Enzymatica AB: Prospekt avseende Enzymaticas företrädesemission offentliggjort Pressreleaser Ladda ner | Visa Stäng
2022-08-05 Enzymatica Enzymatica AB: Publication of prospectus regarding Enzymatica's rights issue Pressreleaser Ladda ner | Visa Stäng
2022-07-20 Penser Access Penser Access: Vändning i sikte - Enzymatica Analyser Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Kvartalsrapport Q2/2022: Förbättrad försäljning skapar tillförsikt Rapporter Ladda ner | Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Interim report Q2/2022: Improved sales give confidence for the future Rapporter Ladda ner | Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of SEK 74.7 million Pressreleaser Ladda ner | Visa Stäng
2022-07-19 Enzymatica Enzymatica AB: Styrelsen i Enzymatica beslutar om nyemission om 74,7 MSEK Pressreleaser Ladda ner | Visa Stäng
2022-06-23 Enzymatica Enzymatica AB: ColdZyme blocks omicron virus - according to new research Pressreleaser Ladda ner | Visa Stäng
2022-06-23 Enzymatica Enzymatica AB: ColdZyme blockerar omikronvirus - enligt ny forskning Pressreleaser Ladda ner | Visa Stäng
2022-06-16 Enzymatica Enzymatica AB: Enzymatica signs loan agreement with major shareholders Pressreleaser Ladda ner | Visa Stäng
2022-06-16 Enzymatica Enzymatica AB: Enzymatica tecknar låneavtal med huvudägare Pressreleaser Ladda ner | Visa Stäng
2022-04-28 Enzymatica Bulletin from Annual General Meeting of Enzymatica AB (publ) on 28 April 2022 Pressreleaser Visa Stäng
2022-04-28 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) den 28 april 2022 Pressreleaser Visa Stäng
2022-04-28 Enzymatica Enzymatica AB: Interim report Q1/2022: Our financial targets remain in place Rapporter Ladda ner | Visa Stäng
2022-04-28 Enzymatica Enzymatica AB: Kvartalsrapport Q1/2022: Våra finansiella mål ligger fast Rapporter Ladda ner | Visa Stäng
2022-04-11 Enzymatica Enzymatica AB: Article about ColdZyme acquitted from suspicions of research misconduct Pressreleaser Ladda ner | Visa Stäng
2022-04-11 Enzymatica Enzymatica AB: Artikel om ColdZyme-studie frias från misstankar om oredlighet i forskning Pressreleaser Ladda ner | Visa Stäng
2022-04-04 Enzymatica Enzymatica AB: Enzymatica's mouth spray to be launched in Turkey Pressreleaser Ladda ner | Visa Stäng
2022-04-04 Enzymatica Enzymatica AB: Enzymaticas munspray lanseras i Turkiet Pressreleaser Ladda ner | Visa Stäng
2022-03-31 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng
2022-03-31 Enzymatica Enzymatica AB: Enzymatica publishes annual report for 2021 Rapporter Ladda ner | Visa Stäng
2022-03-28 Enzymatica Notice of Annual General Meeting 2022 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-03-28 Enzymatica Kallelse till årsstämma 2022 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

17 Feb 2023 | Bokslutskommuniké 2022
27 Apr 2023 | Kvartalsrapport 2023-Q1
4 May 2023 | Årsstämma 2022
18 Jul 2023 | Kvartalsrapport 2023-Q2
7 Nov 2023 | Kvartalsrapport 2023-Q3